Fibroblast Activation Protein Inhibitor Theranostics: A Huge Opportunity with its Fair Share of Oncological Pitfalls-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Fibroblast Activation Protein Inhibitor Theranostics: A Huge Opportunity with its Fair Share of Oncological Pitfalls

Published:2024-06 Issue:02 Volume:23 Page:071-072
ISSN:1450-1147
Container-title:World Journal of Nuclear Medicine
language:en
Short-container-title:World J Nucl Med

Author:

Al-Ibraheem Akram^ORCID

Publisher

Georg Thieme Verlag KG

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0044-1787886.pdf

Reference15 articles.

1. Limitations and pitfalls of FDG-PET/CT in infection and inflammation;J P Pijl;Semin Nucl Med,2021

2. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;H Sung;CA Cancer J Clin,2021

3. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives;X Mao;Mol Cancer,2021

4. FAPI PET/CT: will it end the hegemony of 18F-FDG in oncology?;R J Hicks;J Nucl Med,2021

5. Dimeric FAPI with potential for tumor theranostics;C Qin;Am J Nucl Med Mol Imaging,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP